Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 in primary immune thrombocytopenia
NCT07294365Phase 2Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of birelentinib in immune thrombocytopenia (ITP), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jan 2026; status: recruiting.
02
Drugs
birelentinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07294365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07294365.